Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
Status:
Recruiting
Trial end date:
2024-09-13
Target enrollment:
Participant gender:
Summary
A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK),
pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to <
18 years of age with recently active neuromyelitis optica spectrum disorder (NMOSD) who are
seropositive for autoantibodies against aquaporin-4 (AQP4-immunoglobulin [Ig]G).